Secondary data analysis on the implementation of guideline recommendations for the management of patients with hypercholesterolaemia and cardiovascular risk in routine general practice

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032936

Enrollment

40000

Registered

2023-10-30

Start date

2023-07-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E78

Interventions

Group 1: Patients with hypercholesterolaemia and cardiovascular risk, retrospective analysis of routine data of patients from outpatient practices of the MEDI-Verbund Baden-Württemberg e.V.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patient data collected within the practice data collection period and anonymised.

Exclusion criteria

Exclusion criteria: Lack of anonymisation

Design outcomes

Primary

Measure	Time frame
Evaluating guideline adherence in the management of patients with hypercholesterolaemia and cardiovascular risk in general practice by analysing possible changes in prescribing and treatment modalities regarding the prescription of statins (including dose and prescription of combination products) after the introduction of the new ESC treatment guideline in 2019.	—

Secondary

Measure	Time frame
Measure treatment outcomes (reduction in LDL-C levels, overall cardiovascular risk, reduction in the number of clinically relevant events or diseases (e.g. arterial hypertension, atherosclerosis, coronary heart disease (CHD), heart failure, myocardial infarction (MI), stroke, chronic kidney disease, diabetes mellitus)) and side effects (e.g. nausea, vomiting, and especially muscle pain) before and after publication of the ESC treatment guideline in 2019.	—

Measure

Time frame

Measure treatment outcomes (reduction in LDL-C levels, overall cardiovascular risk, reduction in the number of clinically relevant events or diseases (e.g. arterial hypertension, atherosclerosis, coronary heart disease (CHD), heart failure, myocardial infarction (MI), stroke, chronic kidney disease, diabetes mellitus)) and side effects (e.g. nausea, vomiting, and especially muscle pain) before and after publication of the ESC treatment guideline in 2019.

—

Countries

Germany

Contacts

Public ContactJost;Jost Steinhäuser;Steinhäuser

Institut für Allgemeinmedizin Universitätsklinikum Schleswig-Holstein, Campus Lübeck;Institut für Allgemeinmedizin Universitätsklinikum Schleswig-Holstein, Campus Lübeck

Jost.Steinhaeuser@uksh.de;Jost.Steinhaeuser@uksh.de+4945131018000;+4945131018000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026